Tirzepatide, a dual GIP/GLP-1 receptor agonist, represents the newest class of weight loss medications with remarkable clinical trial results from the SURMOUNT studies (Jastreboff et al., NEJM, 2022)
11,107 After both forms of GLP-1 have been exposed to DPP-IV, they are either rendered inactive or become an antagonist for the GLP-1R
In parallel, there is growing focus on small molecule GLP-1R agonists , which have the potential to be administered orally, produced more cost-effectively, and offer improved stability and pharmacokinetic profiles
If you experience low mood, thoughts of self-harm, or suicidal thoughts, seek urgent medical help contact your GP, call NHS 111, or in an emergency call 999 Patients are encouraged to ask their doctor about the current evidence base, the distinction between trial data and licensed use, and what support will be available if side effects occur
The generic drugstore blend sitting on your shelf right now may do absolutely nothing for the specific disruptions semaglutide causes